Turn Therapeutics Inc. (TTRX)
TTRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TTRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002023016 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that these condensed consolidated financial statements as of September 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern." | 10-Q 2026-11-09 |
| Cash and burn | $9.4M cash; operating cash flow -$1.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 30,572,704 (2026-11-06); 29,445,183 a year earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, Whippany, New Jersey, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $308K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$6.2M | -$1.5M | $9.4M | $7.3M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$5.8M | -$923K | $9.9M | $7.3M | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$971K | -$1.6M | $11.0M | $7.3M | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | $279K | -$1.2M | $4.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$1.9M | -$589K | $514K | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$1.2M | -$500K | $3.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$329K | -$298K | $1.6M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$323K | -$431K | $498K | No debt tags | Needs four quarters | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B5 | 2026-11-16 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-31 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-09 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-10 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-10-19 |
Source: SEC EDGAR submissions feed, 129 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.4% |
| 1 month | -11.8% |
| 3 months | -5.2% |
| Year to date | +137.2% |
| 1 year | +128.5% |
| From 52-week high | -39.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INO | Inovio Pharmaceuticals Inc. | $1.40 | -2.10% | $262.2M |
| PRLD | Prelude Therapeutics Incorporated | $3.41 | -1.16% | $272.1M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier